In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
101 News Items found
Elaine sitting down on a mountain with her border collie between her legs
MSK Nurse Exemplifies Tradition of Filipino Nursing in America

Elaine Mosqueda has traveled far in so many ways since moving from the Philippines to the United States at the age of 21.
MSK radiation oncologist Christopher Barker
Clinical Update
Advanced Basal Cell Carcinoma Responds to Combination Drug-Radiation Treatment

Learn how advanced basal cell carcinoma can be treated with a new combination radiation and drug therapy.
An illustration of sugar pouring onto NRF2
Finding
Sugar Directly Controls a Cancer-Causing Protein, Scientists Find

The discovery suggests a potential new treatment approach for certain cancers.
Detail of an MSK scientist working in a lab
MSK Research Highlights, October 31, 2023

New MSK research identifies a promising immunotherapy target for acute myeloid leukemia; decodes genetic differences in tumors from patients with African ancestry; and finds a virtual mind-body fitness program reduced hospitalizations for those in active cancer treatment. A clinical trial led by MSK also resulted in the approval of a new combination therapy for non-small cell lung cancer.
Alexander Drilon, MD
Precision Medicine Advances: Pivotal Studies Led by MSK Published in the New England Journal of Medicine

Following an approval from the FDA in May 2020, the New England Journal of Medicine has published data from the phase I/II LIBRETTO-001 clinical trial of selpercatinib in advanced RET (REarranged during Transfection)-driven lung and thyroid cancers. MSK’s Alexander Drilon, MD, the recently appointed Chief of the Early Drug Development Service, serves as the lead investigator for multi-site clinical trial.
Physician-scientist Alex Kentsis
In the Lab
Research Shows How Common Feature of Blood Cancers Can Be Targeted

Research points to the role of a protein called MYB, which has long been known to play a role in cancer.
Participants in Cycle for Survival
Treating Rare Cancers

Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.
Luc Morris
New AI Tool Uses Routine Blood Tests To Predict Immunotherapy Response for Many Cancers

Researchers MSK and their collaborators at Mount Sinai have developed an artificial intelligence-based model to predict who will benefit from immune checkpoint inhibitors using only routine blood tests and clinical data.
Physician-scientist Luc Morris
In the Lab
Clearing the Fog around Tumor Mutational Burden

MSK researchers shed light on how the number of mutations in a tumor affect a patient’s response to immunotherapy drugs.
Michelle Bradbury
Toward the Next Generation of Medical Imaging

Memorial Sloan Kettering researchers will explore "C dots" for tumor detection and treatment.